GlobeNewsWire
06 Jul 2026, 10:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has accepted Pharvaris' New Drug Application (NDA) for deucrictibant immediate-release (IR) for the on-demand treatment of Hereditary Angioedema (HAE) attacks. — FDA acceptance of an NDA is a critical regulatory milestone that moves a drug closer to commercialization and revenue generation.
+0.60The pivotal Phase 3 RAPIDe-3 study met its primary and all 11 secondary efficacy endpoints with statistical significance. — Strong clinical data increases the probability of FDA approval and suggests the drug will be competitive in the market.
+0.40The FDA has set a PDUFA target action date of April 23, 2027, for the deucrictibant IR application. — Provides a concrete timeline for the market to price in the binary outcome of approval or rejection.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The FDA has accepted the company's New Drug Application for deucrictibant IR, marking a major milestone toward potential commercialization.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
50m ago
